Committed for Better and Dedicated for Caring All--The Advancing Yangtze River Pharmaceutical Group

Founded in 1971, Yangtze River Pharmaceutical Group (YRPG) is a Chinese giant cross-regional pharmaceutical group combining production-study-research and integrating research, manufacturing and trading, and listed as one of China’s 1st Innovative Enterprises by the Ministry of Science and Technology of the P.R.C. Headquartered in Taizhou City, Jiangsu Province, YRPG now has over 15,000 employees, and covers an area of over 3 million square meters in total, with 15 member companies under it that distribute in Taizhou, Beijing, Shanghai, Nanjing, Guangzhou, Chengdu, Suzhou, and Changzhou, etc., and the marketing network covering provinces, municipalities, and autonomous regions of China except Taiwan, China.

YRPG has been following its mission of “Committed for Better and Dedicated for Caring All” and persisting in “Good Quality, People Oriented, Great Innovation, Supreme Kindness” as the core values. Building the brand culture of “Medicines of Yangtze River to Benefit the Chinese People like Water of Yangtze River Nurtures the Chinese Nation” from a high starting point, YRPG is committed to furnishing the society with quality pharmaceutical products and efficient health services, with composite economic results at the forefront of Jiangsu Province and Chinese pharmaceutical industry continuously for over 10 years since 1996, and achievements of “Top 500 Chinese Enterprises”, “Top 500 Chinese Private Enterprises”, and “Top 500 Chinese Taxpayers”. According to the data published by the Ministry of Industry and Information Technology of the P.R.C., YRPG’s main business income ranked among the top 3 in top 100 enterprises of the Chinese pharmaceutical industry for consecutive 7 years from 2009 to 2015, wherein, it took the first place in 2014 and 2015. It successively won “National May Day Labor Medal”, “National Enterprise of Observing Contract and Valuing Credit”, “National Civilized Unit”, “Jiangsu Quality Award”, and “Nomination Award of the China Quality Award”, etc. In December 2015, it was the only enterprise in the Chinese pharmaceutical industry that won “Light of Quality—Quality Benchmarking Enterprise” upon selection of 6 million people. In 2016, it won “Global Performance Excellence Award” (World Class); on December 12, 2016, YRPG won Top 1 among Chinese biopharmaceutical plate in terms of brand strength (953pts) and brand value (RMB 22.842 billion) as the Chinese brand value rankings were revealed.

YRPG regards R&D innovation as the strategic basis for enterprise development, and devotes itself to the R&D of Chinese Category 1 new drugs and innovative drugs. It adheres to the innovation path, and comprehensively advances the “three medicines in one go” strategy in new drug R&D: it invests 3~4% of its annual sales revenue into new drug R&D to seize the sci-tech commanding point, and introduces high-end talents who are innovative in R&D and have international vision to establish the international R&D system. Depending on the innovation R&D platforms including key state-level laboratory for new technologies of pharmaceutical preparations and key laboratory for TCM quality control, etc., it has over 100 chemical innovative drugs, generic drugs, TCMs, and biological drugs in development, to ensure the orderly conduct of the short-term, medium-term, and long-term product R&D. Its product system covers over 10 fields, over 10 dosage forms, and over 200 specifications through years of accumulation and innovation. YRPG, always oriented by market, mainly develops anti-infection, cardiovascular, and digestive system products, and is actively developing other drug markets with growth potential.

YRPG is accelerating the implementation of high-end preparation internationalization project. There have been 7 varieties (Omeprazole Enteric-coated Capsules, Enalapril Maleate Tablets, Ginkgo Leaf Tablets, Ginkgo Leaf Extract, Nifedipine Sustained-release Tablets, Glimepiride Tablets, and Sotalol Hydrochloride Tablets) of 4 workshops passing EU GMP certification since 2010, with quality of over 20 products reaching standards of European and American pharmacopoeias. And its Esomeprazole Sodium for Injection and API are now being registered with the U.S. FDA, Pantoprazole Sodium for Injection is being applied for MA in the Europe, and Parecoxib Sodium for Injection and Omeprazole Enteric-coated Capsules are being registered with Australian TGA.

Looking into the future, the advancing YRPG makes revitalizing national medicine its mission, and sincerely serves the health of the humanity with a scientific, rigorous, and responsible attitude. Resonating with China’s strategy during the 13^th Five-year Plan period, YRPG will strain every nerve to build the “Long Feng Tang” TCM kingdom, accelerate the transformation from “Made by Yangtze River” to “Created by Yangtze River”, and endeavor to stride toward the vision and goal of becoming a “world-class pharmaceutical enterprise that is strongest in China”.